We’re aiming to take the wind out of PAH.
And you’re invited.

Ask about joining the IMPAHCT trial today.
The hope is real.

Patient Information

This brochure contains information about the IMPAHCT Study for people with pulmonary arterial hypertension. This information should help you decide whether you or someone you know may want to take part in this study.

What is a clinical research study?

A clinical research study is a medical study that helps to answer important questions about an investigational medication, such as:

• Does it work?
• What amount, or dose, may work best?
• How safe is it?
• Are there side effects?

Deciding to take part in a clinical research study is your decision. If you have any questions, you can contact the study team using the information provided in this brochure.

All medications must be tested in clinical research studies before they can be approved to prescribe to patients. Without people taking part in these studies, we would have no new medications.
About the IMPAHCT Study

This clinical research study is looking at a potential new medication (an "investigational medication") for pulmonary arterial hypertension (PAH). The investigational medication contains a substance that has been approved to treat other medical conditions. It is being formulated as an inhaled medication for patients with PAH. This inhaled medication is only available to participants of this clinical research study. The study aims to find out which dose (strength) of the investigational medication:

- is safe and tolerable, and
- works best in people with PAH.

Why is the IMPAHCT Study important?

Most of the currently available therapies for PAH help to relieve the symptoms but do not significantly reverse the damage caused by PAH to the blood vessels in the lungs. Therefore, there is a critical need to research potential new treatments for PAH. The aim of the investigational medication is to target the underlying cause of PAH using an approach different from the currently available treatments.

What will the IMPAHCT Study involve?

If you are eligible and take part, you will be in the IMPAHCT Study for up to about 7 months (32 weeks).

- You will have at least 8 study visits, including 3 remote visits (by phone).
- You will receive either the investigational medication or a placebo. A placebo looks the same as the investigational medication but contains no active medication.
- You will take the study drug (the investigational medication or placebo) using a dry powder inhaler twice every day.
- You may continue taking most, if not all, of your current PAH medications during the study.
The study has 3 periods.

**Screening period**
(up to 28 days)
- You will visit the study center to see if the study is suitable for you and whether you want to take part.

**Study treatment period**
(about 24 weeks)
- You will take the study drug using an inhaler twice every day, once each in the morning and evening.
- You will have 7 visits for study assessments. These visits will include both study center visits and phone calls.

**Long-term extension study or safety follow-up period**
- Upon completion of the study treatment period, you may have an option to continue into a long-term extension (LTE) study. In the LTE study, all participants will receive the investigational medication until it is commercially available.
- Alternatively, if you do not take part in the LTE study, you will receive 1 final phone call for study assessments, about 28 days after the study treatment period is complete.

**Who can take part?**
You or someone you care for may be able to take part if you/they:
- are 18–75 years of age
- have been diagnosed with PAH
- have been receiving stable doses of at least 2 PAH medications for at least the past 90 days
What else do I need to consider?

- The study team will explain the possible benefits and risks of the study.
- You do not have to take part in the study if you do not want to.
- If you choose to take part in the study, you can stop participating at any time.
- You will not be paid to take part in this study, but you may be reimbursed for reasonable travel costs during your participation.
- The study drug and all study-related tests and assessments will be provided at no cost to you.
- A team of doctors and nurses will monitor your health carefully during the study.

How do I get more information?

To find out more, please contact us.

Study participation is voluntary. By contacting us, you are under no obligation to take part in this study.

Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT)